FDA
-
-
-
-
-
-
-
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
-
-
-
-
-
-
-
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Scholar Rock stock falls after FDA flags issues at manufacturing facility
-
-
-
-
-
-
-
Barclays Starts Scholar Rock (SRRK) at Overweight
-
-
-
-
-
-
-
Scholar Rock Holding (SRRK) Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
-
-
-
-
-
-
-
Scholar Rock Holding Corp. (SRRK): FDA Grants Priority Review for BLA and EMA Accepts MAA for Apitegromab as a Treatment for SMA
-
-
-
-
-
-
-
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
-
323,908 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
